RCAMU
ESPR

Rothschild & Co Asset Management US’s Esperion Therapeutics ESPR Stock Holding History

Rothschild & Co Asset Management US’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-393,839
Closed -$14.6M – 295
2020
Q3 		$14.6M Sell
393,839
-33,429
-8% -$1.32M 0.26% 157
2020
Q2 		$21.9M Buy
427,268
+39,685
+10% +$1.66M 0.32% 123
2020
Q1 		$12.2M Buy
387,583
+92,502
+31% +$4.88M 0.19% 190
2019
Q4 		$17.6M Buy
295,081
+278,834
+1,716% +$12.5M 0.18% 204
2019
Q3 		$596K Sell
16,247
-149
-0.9% -$5.9K 0.01% 331
2019
Q2 		$763K Sell
16,396
-217
-1% -$10.2K 0.01% 327
2019
Q1 		$667K Sell
16,613
-10,513
-39% -$472K 0.01% 344
2018
Q4 		$1.25M Sell
27,126
-255
-0.9% -$12.3K 0.02% 341
2018
Q3 		$1.22M Buy
27,381
+3,644
+15% +$167K 0.01% 353
2018
Q2 		$930K Buy
23,737
+4,818
+25% +$243K 0.01% 358
2018
Q1 		$1.37M Sell
18,919
-1,952
-9% -$143K 0.02% 335
2017
Q4 		$1.37M Sell
20,871
-1,554
-7% -$83.7K 0.01% 329
2017
Q3 		$1.12M Buy
+22,425
New +$1.08M 0.01% 324

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Rothschild & Co Asset Management US's ESPR Position: Q4 2020 in Review

Rothschild & Co Asset Management US sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 393,839 shares — an estimated $14.6M sold.

Rothschild & Co Asset Management US first reported a position in ESPR in Q3 2017 and held it in 13 quarters. The position peaked at $21.9M in Q2 2020. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • Rothschild & Co Asset Management US reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 393,839 Esperion Therapeutics shares in Q4 2020, an estimated $14.6M.
  • Rothschild & Co Asset Management US first reported a position in Esperion Therapeutics in Q3 2017 and held it in 13 quarters.
  • Rothschild & Co Asset Management US's Esperion Therapeutics position peaked at $21.9M in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2020, filed 8 Feb 2021.